Zug, Switzerland: Galderma will present new data on Relfydess (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator created
Zug, Switzerland: Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent
Zug, Switzerland: Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in
Zug, Switzerland: Galderma celebrates the 25th anniversary of the approval of Sculptra®, the first proven regenerative biostimulator, with new
Socially Bharat is your comprehensive source for Social news, NGO’s, and expert insights from across India.
Copyright© 2025 Creative Bharat Powered By A Buzz Company